Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.
Luke A. Jelen, David J Lythgoe, James Stone, Allan H. Young, Mitul A. Mehta
Nature Medicine July 24, 2025 DOI: 10.1038/s41591-025-03800-w (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind crossover study Randomized Peer reviewed |
|---|---|
| Sample size | 26 |
| Population | Adults with major depressive disorder |
| Interventions | Naltrexone Ketamine |
| Dose | 50 mg naltrexone, 0.5 mg per kg ketamine |
| Topics | Ketamine Depression Esketamine |
| Keywords | Depression treatment Opioid system Mechanism of action |
| Citations | 29 |
| Registration | NCT04977674 |
| Key points | Naltrexone attenuated the ketamine-induced increase in glutamatergic activity in the anterior cingulate cortex and reduced the antidepressant effect on day 1, indicating the opioid system modulates ketamine's acute and sustained effects. |
Abstract
We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50 mg naltrexone before an intravenous infusion of 0.5 mg per kg ketamine. Brain glutamatergic activity in the anterior cingulate cortex was measured using functional magnetic resonance spectroscopy and depressive symptoms were assessed with the Montgomery-Åsberg Depression Rating Scale. Naltrexone attenuated the increase in glutamate + glutamine to total N-acetylaspartate ratio during ketamine infusion compared to placebo (F1,253 = 4.83, P = 0.029) and also attenuated the reduction in Montgomery-Åsberg Depression Rating Scale scores on day 1 (condition-by-time interaction, F1,74 = 5.39, P = 0.023). These findings demonstrate that the opioid system modulates the acute response to ketamine and subsequent antidepressant effects. Interactions between the glutamate and opioid systems may have implications for the development of new depression treatment strategies. ClinicalTrials.gov registration: NCT04977674 .
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.
Citations in the library
Cited by 22
- Rapid antidepressant potential of nitrous oxide: current state and major questions. Molecular Psychiatry June 1, 2026
- Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry June 1, 2026
- Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology Advanced Science December 14, 2025
- Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets. Cell April 30, 2026
- Methodological considerations for interpreting ketamine-naltrexone trials in depression The International Journal of Neuropsychopharmacology October 1, 2025
and 17 more in the library
Cites 24
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress 1998
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism American Journal of Psychiatry August 29, 2018
- Ketamine: a paradigm shift for depression research and treatment Neuron March 1, 2019
and 19 more in the library